MapLight Therapeutics Starts $100 Million IPO Effort For CNS Treatments

MapLight Therapeutics is a clinical-stage biopharma focused on CNS disorders and has filed for a $100M U.S. IPO to fund its ...

Vertex Pharmaceuticals: I'm Downgrading To Hold On Drug Pricing, Pipeline Concerns

Vertex faces pressure from potential U.S. drug pricing reforms and tariffs. Click here to find out why VRTX stock is a Hold.

Friends Who Like 'Big Guys' Are in Luck! A Look at Four Mid- to Large-Sized SUVs Set to Launch

At this year's Shanghai Auto Show, FAW-Volkswagen has brought a great gift for fans who love "big guys"—the all-new mid- to ...
PharmiWeb

Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025

Ocrevus subcutaneous maintains consistent benefit-risk profile after two years -- New late-breaking data confirms Ocrevus ...

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS) following switch to Kesimpta after ...